Litvack Frank 4
4 · CAPRICOR THERAPEUTICS, INC. · Filed Feb 23, 2023
Insider Transaction Report
Form 4
Litvack Frank
Director
Transactions
- Exercise/Conversion
Common Stock
2023-02-21$1.39/sh+14,027$19,498→ 141,800 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-02-21−14,027→ 0 totalExercise: $1.39Exp: 2023-02-22→ Common Stock (14,027 underlying) - Tax Payment
Common Stock
2023-02-21$4.31/sh−4,524$19,498→ 137,276 total
Footnotes (3)
- [F1]Represents a "net exercise" of outstanding stock options. These shares were withheld by the Issuer for payment of the exercise price, based on the closing market price of the Issuer's common stock on February 21, 2023 of $4.31. The options would otherwise expire on February 22, 2023, pursuant to their terms.
- [F2]This option was granted on February 22, 2013 and was previously reported as covering 140,270 shares at an exercise price of $0.37 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice to $1.39 per share that occurred on February 12, 2020.
- [F3]25% of the shares vested immediately, with the remainder vesting monthly over 25 months commencing May 1, 2013.